Prostate Cancer

PSA-based screening for prostate cancer among men older than 50 has decreased since the 2012 USPSTF recommendations.

Thanks to the efforts of the Prostate Cancer Foundation and Movember, men of good will (especially those inclined to grow mustaches and raise awareness and funds each year) and their physicians are newly energized to make progress.

Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223 and review the available data regarding the cost of denosumab compared with that of zoledronic acid.

Enhanced control of osseous metastases with both systemic life-extending therapies and bone-support medications has meaningful clinical impact for prostate cancer patients.

A study showed that prostate cancer patients with bone metastases could have a long-term response to ADT and an acceptable quality of life for 10 or more years.

A small study found that the detection of AR-V7 in advanced prostate cancer patients is not associated with resistance to initial chemotherapy.

Men with prostate cancer assigned to intermittent ADT experienced more ischemic and thrombotic events than did men assigned to continuous ADT.

In this video, Dr. Nicholas David James discusses the results of the STAMPEDE trial, which tested front-line docetaxel combined with hormonal therapy in patients with advanced, hormone-naive prostate cancer.

Assigning prostate cancer patients in relapse after prostatectomy to ADT and radiation therapy delayed disease progression compared to radiation therapy alone.

Researchers have identified a new histologic subset of metastatic castration-resistant prostate cancer that is refractory to androgen receptor inhibition.

Immediate ADT improved overall survival compared with delayed ADT in prostate cancer patients with a rising prostate-specific antigen level.

The addition of docetaxel and prednisone to standard therapy may be the first effective adjuvant chemotherapy treatment for high-risk prostate cancer patients.

Ahead of the 2015 ASCO Annual Meeting, we are discussing the role of immunotherapy in genitourinary cancers with Susan F. Slovin, MD, PhD.

A large majority of prostate tumors sequenced as part of a comprehensive precision medicine study have mutations that can be targeted with available therapies.

At worst radical prostatectomy is equal to radiation therapy in operable very-high-risk prostate cancer, and there are accumulating data to suggest that a surgery-first approach is better induction for multimodal therapy.

It is our opinion that surgery is inappropriate for very-high-risk prostate cancer and that a combination of EBRT and ADT should be the preferred treatment modality.

The STAMPEDE trial suggests that survival can be improved in metastatic prostate cancer patients with the addition of docetaxel to frontline hormonal therapy.

Disease progression among prostate cancer patients starting androgen deprivation therapy (ADT) was delayed by 10 months in patients already receiving statins.

Men with metastatic castration-resistant prostate cancer that had mutations in DNA repair genes were more likely to respond to the PARP inhibitor olaparib.

Too many people are being screened, diagnosed, and treated for certain types of cancer, according to two cancer researchers.

Adding cixutumumab to ADT did not significantly increase the undetectable PSA rate in men with newly diagnosed metastatic hormone-sensitive prostate cancer.

Men with high midlife cardiorespiratory fitness have a lower incidence of lung and colorectal cancer; however, this association was not seen for prostate cancer.

A combination of biomarkers has shown promise as a surrogate for survival in clinical trials of metastatic castration-resistant prostate cancer.

A new study suggests that men with a history of cardiovascular disease prior to starting ADT are at risk for such events during the first 6 months of treatment.

At this year’s ASCO GU Cancers Symposium, several high-impact and potentially practice-changing abstracts were presented during the prostate cancer session.

Women with a first-degree relative diagnosed with prostate cancer may be at increased risk for developing breast cancer, according to a new study.

A reduction in testosterone levels in the first year of ADT correlates with improved survival in prostate cancer patients being treated for biochemical failure.

As part of our coverage of the ASCO GU Cancers Symposium, we discuss decision-making in the management of patients with early-stage prostate cancer.

The 4Kscore blood test has been shown to accurately detect the presence of high-grade prostate cancer, according to a study presented at ASCO GU.

Two clinical factors may predict PSA response to cabazitaxel in men with metastatic castration-resistant prostate cancer.